Global Hemophilia Market Report: 2013 Edition- New Report by Koncept Analytics

Sept. 24, 2013 - PRLog -- Hemophilia is a disorder in which the blood does not clot properly, leading to extended bleeding. The bleeding can be external or internal, especially in the knees, ankles, and elbows. There are two types of hemophilia: type A and type B. The market has been growing since past several years mainly due to improvement in technology, discovery of new coagulation factors, proteins, and plasma concentrates which are being used for treating chronic diseases and medical conditions.

As more people suffer with Hemophilia A in comparison with Hemophilia B and Inhibitors, the Hemophilia A market is the largest in the world. The US accounts for the major population suffering with hemophilia globally.

The key trends observed within the market include inclination towards prophylaxis, long-acting factor VIII and IX development and growing penetration of rFVIII products in emerging markets which is a opportunity for manufacturers. On the development front, there has been an increase in the launch of new products by various companies. But there are certain challenges which the industry is facing as of now which include risk of antibody neutralization, emerging challenges for developing nations and rising cost of hemophilia treatment. The major factors which will contribute in the growth of the industry include rising male population, increasing expenditure on healthcare and increasing new patient registration.

The report studies the hemophilia market on a global scale and its various segments. The competition in the global hemophilia market is intense with few large players viz. Baxter, Grifols, Pfizer and Nova Noridisk. The competitive landscape along with the company profiles of the leading players in the market is discussed in detail.

This report comprises following sections:

1. Hemophilia: An Overview

-Sign & Symptoms

-Types of Hemophilia

-Treatment

2. Market Overview

2.1 Global Hemophilia Market

-Market Value

-Patient Volume

2.2 Hemophilia Market by Segments

2.2.1 Hemophilia A

-Market Value

-Patient Volume

-Key Products Comparison

-FVIII Market

2.2.2 Hemophilia B

-Market Value

-Patient Volume

-Key Products Comparison

-FIX Market

2.2.3 Hemophilia with Inhibitor

-Market Value

-Patient Volume

-Key Products

2.2.4 Von Willebrand Disease

2.3 Hemophilia Market by Region

2.3.1 Australia

2.3.2 The US

-Market Value

-Patient Volume

-Market Segments

-FVIII Market

-FIX Market

3. Market Dynamics

3.1 Key Trends

3.1.1 Shift towards Prophylaxis

3.1.2 Long-Acting Factor VIII and IX Development

3.1.3 Rising Penetration of rFVIII Products in Emerging Markets

3.2 Growth Drivers

3.2.1 Rising Male Population

3.2.2 Increasing Expenditure on Healthcare

3.2.3 Increasing New Patient Registration

3.3 Significant Developments

3.3.1 Baxter Announced ADVATE Approval in China

3.3.2 Baxter Expands Access to Recombinant FVIII Hemophilia Treatment in Brazil

3.3.3 Novo Nordisk Files New Hemophilia Drug in EU, US

3.4 Challenges

3.4.1 Risk of Antibody Neutralization

3.4.2 Emerging Challenges for Developing Nations

3.4.3 Rising Cost of Hemophilia Treatment

4. Competitive Scenario

-Market Share

-Product Comparison

5. Company Profiles

5.1 Baxter International Inc.

5.1.1 Business Overview

5.1.2 Financial Overview

5.1.3 Business Strategies

-Advancement of Core Portfolio

-Expansion of Product Portfolio

5.2 Grifols

5.2.1 Business Overview

5.2.2 Financial Overview

5.2.3 Business Strategies

-Expansion in Other Geographic Regions

-Growth through Mergers & Acquisitions

5.3 Novo Nordisk

5.3.1 Business Description

5.3.2 Financial Highlights

5.3.3 Business Strategies

-Product Innovation

5.4 Pfizer, Inc.

5.4.1 Business Overview

5.4.2 Financial Highlights

5.4.3 Business Strategies

-Expansion in Emerging Markets

-Growth through Acquisitions

6. Market Outlook

6.1 Market Forecast

6.2 Forecast Methodology

6.2.1 Dependent and Independent Variables

6.2.2 Correlation Analysis

6.2.3 Regression Analysis

List of Charts

Types of Hemophilia

Worldwide Patients Treated with Hemophilia (2010-2012E)

Global Hemophilia Treatment Market Revenues (2008-2013E)

Worldwide Patients Treated with Hemophilia A (2010-2012E)

Global Hemophilia A Market Size (2010-2012E)

Global Recombinant FVIII Market Revenues (2005-2012E)

Worldwide Patients Treated with Hemophilia B (2010-2012E)

Global Hemophilia B Market Size (2010-2012E)

Global Recombinant FIX Market Size (2006-2012E)

Global Recombinant FIX Consumption (2005-2011)

Global Recombinant FIX Consumption Market Share (2011)

Worldwide Patients Treated with Inhibitor (2010-2012E)

Global Inhibitor Market Size (2010-2013E)

Demand of Plasma Derived Factor IX in Australia (2008-2012)

Demand of Recombinant Factor IX in Australia (2008-2012)

Number of Hemophilia Patients Treated in the US (2010-2012E)

The US Hemophilia Market Value (2010-2012E)

Global Male Population (2005-2014F)

Healthcare Expenditure Worldwide (2005-2012E)

New Patient Registrations in Global Bleeding Disorders Market (2008-2012)

Global Hemophilia Market Share (2011)

Global Recombinant Coagulation (FVII, FVIII, FIX) Market (2011)

Global Recombinant FVIII Market Share (2012E)

Baxter’s Revenue by Business Segments (2012)

Baxter’s Revenues and Net Income (2008-2012)

Grifols Revenue Share by Business Segments (2012)

Grifols Revenue Share by Geographical Segments (2012)

Grifols’ Revenues & Net Profit (2008-2012)

Novo Nordisk’s Revenue Share by Business Segments (2012)

Novo Nordisk’s Revenue Share by Region (2012)

Sales and Net Income of Novo-Nordisk (2008-2012)

Pfizer’s Revenue Share by Business Segments (2012)

Pfizer’s Revenue Share by Geographical Segments (2012)

Pfizer’s Revenues & Net Income (2008-2012)

Global Hemophilia Treatment Market Forecast (2011-2016F)

List of Tables

Revenues of Key Products in Hemophilia A Treatment Market (2011-2016F)

Products for Hemophilia A Treatment

Products for Treatment of Hemophilia B

Inhibitor Treatment (2010-2012E)

US Hemophilia Market by Segments (2010-2012E)

Volume of FVIII Market in the US (2008-2012)

US FIX Consumption (2005-2011)

US Factor (M IU) Consumption by Treatment Type and Patient Age (2012-2020)

Hemophilia A patients by Treatment Category (2012)

Long Acting FIX & FVIII in Early and Late-Stage Development

% Conversion to Recombinant Factor VIII Products in Selected Countries (2011)

Competition in Hemophilia A Market – Emerging Products

Competition in Hemophilia B Market – Emerging Products

Competition in Inhibitor Market – Emerging Products

Competition in von Willebrand Market – Emerging Products

Dependent & Independent Variables (2008-2012)

Correlation Matrix

Model Summary – Coefficient of Determination

Regression Coefficients Output

For further details, kindly visit: http://www.konceptanalytics.com/reportDetail.aspx?reportID=486